Literature DB >> 21741123

Ataxin-2 intermediate-length polyglutamine: a possible risk factor for Chinese patients with amyotrophic lateral sclerosis.

Yongping Chen1, Rui Huang, Yuan Yang, Ke Chen, Wei Song, Pinglei Pan, Jianpeng Li, Hui-Fang Shang.   

Abstract

Intermediate-length polyglutamine (polyQ) expansions in the ataxin-2 (ATXN2) gene have recently been identified as a risk factor for sporadic amyotrophic lateral sclerosis (SALS). Our study aims to analyze cytosine, adenine, guanine (CAG)n expansions in the ATXN2 gene among Chinese patients with SALS. All patients diagnosed with adult-onset sporadic amyotrophic lateral sclerosis (ALS) were consecutively followed up, and their clinical characteristics were collected. To measure the repeat length of ATXN2 polyQ, fluorescence-polymerase chain reaction products were analyzed on a 3100-Avant Genetic Analyzer Applied Biosystem (Foster City, CA, USA) using the ROC-500 size standard. Three hundred forty-five patients with SALS were studied. The mean age of onset was 51.38 ± 12.45 years. ATXN2 polyQ with a repeat length greater than 27 was found to be weakly associated with amyotrophic lateral sclerosis in our study. There was no significant difference in mean age of onset, gender, and onset site between the group of SALS patients with and without ATXN2 polyQ expansion greater than 27. Our finding provides evidence that the ATXN2 polyQ expansion greater than 27 might be a risk factor for Chinese SALS patients.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21741123     DOI: 10.1016/j.neurobiolaging.2011.05.015

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  19 in total

Review 1.  Local RNA translation at the synapse and in disease.

Authors:  Liqun Liu-Yesucevitz; Gary J Bassell; Aaron D Gitler; Anne C Hart; Eric Klann; Joel D Richter; Stephen T Warren; Benjamin Wolozin
Journal:  J Neurosci       Date:  2011-11-09       Impact factor: 6.167

2.  Amyotrophic lateral sclerosis and spinocerebellar ataxia type 2 in a family with full CAG repeat expansions of ATXN2.

Authors:  Sirinan Tazen; Karla Figueroa; Justin Y Kwan; Jill Goldman; Ann Hunt; Jacinda Sampson; Laurie Gutmann; Stefan M Pulst; Hiroshi Mitsumoto; Sheng-Han Kuo
Journal:  JAMA Neurol       Date:  2013-10       Impact factor: 18.302

Review 3.  Clinical neurogenetics: amyotrophic lateral sclerosis.

Authors:  Matthew B Harms; Robert H Baloh
Journal:  Neurol Clin       Date:  2013-11       Impact factor: 3.806

4.  Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers.

Authors:  Marka van Blitterswijk; Bianca Mullen; Michael G Heckman; Matthew C Baker; Mariely DeJesus-Hernandez; Patricia H Brown; Melissa E Murray; Ging-Yuek R Hsiung; Heather Stewart; Anna M Karydas; Elizabeth Finger; Andrew Kertesz; Eileen H Bigio; Sandra Weintraub; Marsel Mesulam; Kimmo J Hatanpaa; Charles L White; Manuela Neumann; Michael J Strong; Thomas G Beach; Zbigniew K Wszolek; Carol Lippa; Richard Caselli; Leonard Petrucelli; Keith A Josephs; Joseph E Parisi; David S Knopman; Ronald C Petersen; Ian R Mackenzie; William W Seeley; Lea T Grinberg; Bruce L Miller; Kevin B Boylan; Neill R Graff-Radford; Bradley F Boeve; Dennis W Dickson; Rosa Rademakers
Journal:  Neurobiol Aging       Date:  2014-05-02       Impact factor: 4.673

5.  Poly-A binding protein-1 localization to a subset of TDP-43 inclusions in amyotrophic lateral sclerosis occurs more frequently in patients harboring an expansion in C9orf72.

Authors:  Leeanne McGurk; Virginia M Lee; John Q Trojanowksi; Vivianna M Van Deerlin; Edward B Lee; Nancy M Bonini
Journal:  J Neuropathol Exp Neurol       Date:  2014-09       Impact factor: 3.685

Review 6.  Spinocerebellar ataxia type 2: clinical presentation, molecular mechanisms, and therapeutic perspectives.

Authors:  J J Magaña; L Velázquez-Pérez; B Cisneros
Journal:  Mol Neurobiol       Date:  2012-09-21       Impact factor: 5.590

7.  ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications.

Authors:  Michael P Hart; Aaron D Gitler
Journal:  J Neurosci       Date:  2012-07-04       Impact factor: 6.167

8.  Distinct TDP-43 pathology in ALS patients with ataxin 2 intermediate-length polyQ expansions.

Authors:  Michael P Hart; Johannes Brettschneider; Virginia M Y Lee; John Q Trojanowski; Aaron D Gitler
Journal:  Acta Neuropathol       Date:  2012-04-21       Impact factor: 17.088

Review 9.  Drosophila as an In Vivo Model for Human Neurodegenerative Disease.

Authors:  Leeanne McGurk; Amit Berson; Nancy M Bonini
Journal:  Genetics       Date:  2015-10       Impact factor: 4.562

10.  Repeats expansions in ATXN2, NOP56, NIPA1 and ATXN1 are not associated with ALS in Africans.

Authors:  Melissa Nel; Thandeka Mavundla; Kayleigh Gultig; Gerrit Botha; Nicola Mulder; Michael Benatar; Joanne Wuu; Anne Cooley; Jason Myers; Evadnie Rampersaud; Gang Wu; Jeannine M Heckmann
Journal:  IBRO Neurosci Rep       Date:  2021-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.